News
MRUS
94.02
-3.00%
-2.91
Genmab ends development of late-stage oncology asset acasunlimab
Seeking Alpha · 6h ago
Weekly Report: what happened at MRUS last week (1222-1226)?
Weekly Report · 12h ago
Major Biotech Player Quietly Ramps Up Its Stake in Merus
TipRanks · 6d ago
Weekly Report: what happened at MRUS last week (1215-1219)?
Weekly Report · 12/22 09:16
Major Investor Makes Bold Move With Fresh Buy-In to Merus Stock
TipRanks · 12/19 02:03
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Barchart · 12/16 12:17
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Merus (MRUS)
TipRanks · 12/15 19:30
Weekly Report: what happened at MRUS last week (1208-1212)?
Weekly Report · 12/15 09:18
Merus Acquired by Genmab, Leadership Changes Announced
TipRanks · 12/12 13:18
*Genmab: Previously Announced Offer is For $97 Per Merus Common Share
Dow Jones · 12/12 06:39
*Genmab: Acquisition Will Drive Revenue, Boost Evolution as Biotech Leader
Dow Jones · 12/12 06:39
*Genmab Completes Takeover Offer for Merus
Dow Jones · 12/12 06:38
*Genmab: All Conditions of Takeover Satisfied
Dow Jones · 12/12 06:38
Genmab Completes Tender Offer for Merus Shares
Reuters · 12/12 06:35
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Barchart · 12/12 00:36
Insider Moves: Merus Executive Sells Significant Stock Holdings
TipRanks · 12/11 02:07
Merus Shareholders Approve Genmab Acquisition Proposal
TipRanks · 12/09 21:39
Weekly Report: what happened at MRUS last week (1201-1205)?
Weekly Report · 12/08 09:17
Genmab Closes $2.5 Billion Notes Offering to Fund Merus Acquisition
Reuters · 12/03 20:03
Weekly Report: what happened at MRUS last week (1124-1128)?
Weekly Report · 12/01 09:16
More
Webull provides a variety of real-time MRUS stock news. You can receive the latest news about Merus through multiple platforms. This information may help you make smarter investment decisions.
About MRUS
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.